Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
83
ARQT Quote, Financials, Valuation and Earnings
Last price:
$29.44
Seasonality move
:
35.97%
Day range:
$29.14 - $29.55
52-week range:
$11.13 - $31.77
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.83x
P/B ratio:
22.81x
Volume:
1.4M
Avg. volume:
2.3M
1-year change:
96.46%
Market cap:
$3.6B
Revenue:
$196.5M
EPS (TTM):
-$0.35
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$87M | -$0.09 | 53.91% | -88.43% | $31.63 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.97% | -56.04% | $25.67 |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$212.9M | $1.77 | 21.97% | 68.6% | $109.25 |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
EDIT
Editas Medicine, Inc.
|
$4.9M | -$0.38 | -72.38% | -61.06% | $5.13 |
|
FOLD
Amicus Therapeutics, Inc.
|
$165.7M | $0.12 | 20.08% | 236.17% | $15.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$29.44 | $31.63 | $3.6B | -- | $0.00 | 0% | 11.83x |
|
ADMA
ADMA Biologics, Inc.
|
$19.53 | $25.67 | $4.6B | 22.93x | $0.00 | 0% | 9.83x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$82.11 | $109.25 | $1.8B | 50.36x | $0.00 | 0% | 2.01x |
|
CRMD
CorMedix, Inc.
|
$12.19 | $19.00 | $960.4M | 5.94x | $0.00 | 0% | 4.10x |
|
EDIT
Editas Medicine, Inc.
|
$2.21 | $5.13 | $215.7M | -- | $0.00 | 0% | 4.05x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.25 | $15.25 | $4.4B | -- | $0.00 | 0% | 7.29x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.694 | 5.02% | 3.07x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
ANIP
ANI Pharmaceuticals, Inc.
|
55.53% | -0.550 | 30.7% | 2.40x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
EDIT
Editas Medicine, Inc.
|
85.41% | 3.856 | 24.32% | 2.81x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | 0.379 | 18.22% | 1.91x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ANIP
ANI Pharmaceuticals, Inc.
|
$111.8M | $22.8M | 3.31% | 8.22% | 10.02% | $37.9M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
EDIT
Editas Medicine, Inc.
|
$6.8M | -$24.5M | -149.99% | -246.73% | -325.44% | -$31.3M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
Arcutis Biotherapeutics, Inc. vs. Competitors
-
Which has Higher Returns ARQT or ADMA?
ADMA Biologics, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 27.14%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About ARQT or ADMA?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 7.9%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 31.69%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 ADMAADMA Biologics, Inc.3 0 0 -
Is ARQT or ADMA More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock ARQT or ADMA?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or ADMA?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 22.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 11.83x versus 9.83x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M ADMAADMA Biologics, Inc.9.83x 22.93x $134.2M $36.4M
-
Which has Higher Returns ARQT or ANIP?
ANI Pharmaceuticals, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 10.59%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat ANI Pharmaceuticals, Inc.'s return on equity of 8.22%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M ANIPANI Pharmaceuticals, Inc.49.07% $1.13 $1.1B -
What do Analysts Say About ARQT or ANIP?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 7.9%. On the other hand ANI Pharmaceuticals, Inc. has an analysts' consensus of $109.25 which suggests that it could grow by 35.33%. Given that ANI Pharmaceuticals, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ANI Pharmaceuticals, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 ANIPANI Pharmaceuticals, Inc.4 1 0 -
Is ARQT or ANIP More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison ANI Pharmaceuticals, Inc. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.639%.
-
Which is a Better Dividend Stock ARQT or ANIP?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ANI Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. ANI Pharmaceuticals, Inc. pays out 8.77% of its earnings as a dividend. ANI Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ARQT or ANIP?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than ANI Pharmaceuticals, Inc. quarterly revenues of $227.8M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than ANI Pharmaceuticals, Inc.'s net income of $24.1M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while ANI Pharmaceuticals, Inc.'s PE ratio is 50.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 11.83x versus 2.01x for ANI Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M ANIPANI Pharmaceuticals, Inc.2.01x 50.36x $227.8M $24.1M
-
Which has Higher Returns ARQT or CRMD?
CorMedix, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 49.9%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ARQT or CRMD?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 7.9%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 55.87%. Given that CorMedix, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe CorMedix, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 CRMDCorMedix, Inc.4 0 0 -
Is ARQT or CRMD More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock ARQT or CRMD?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or CRMD?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 11.83x versus 4.10x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M CRMDCorMedix, Inc.4.10x 5.94x $104.3M $108.6M
-
Which has Higher Returns ARQT or EDIT?
Editas Medicine, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of -332.98%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat Editas Medicine, Inc.'s return on equity of -246.73%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M EDITEditas Medicine, Inc.90.44% -$0.28 $92.2M -
What do Analysts Say About ARQT or EDIT?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 7.9%. On the other hand Editas Medicine, Inc. has an analysts' consensus of $5.13 which suggests that it could grow by 131.9%. Given that Editas Medicine, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Editas Medicine, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 EDITEditas Medicine, Inc.6 7 0 -
Is ARQT or EDIT More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison Editas Medicine, Inc. has a beta of 2.441, suggesting its more volatile than the S&P 500 by 144.07%.
-
Which is a Better Dividend Stock ARQT or EDIT?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Editas Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or EDIT?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are larger than Editas Medicine, Inc. quarterly revenues of $7.5M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is higher than Editas Medicine, Inc.'s net income of -$25.1M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Editas Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 11.83x versus 4.05x for Editas Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M EDITEditas Medicine, Inc.4.05x -- $7.5M -$25.1M
-
Which has Higher Returns ARQT or FOLD?
Amicus Therapeutics, Inc. has a net margin of 7.47% compared to Arcutis Biotherapeutics, Inc.'s net margin of 10.24%. Arcutis Biotherapeutics, Inc.'s return on equity of -29.4% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About ARQT or FOLD?
Arcutis Biotherapeutics, Inc. has a consensus price target of $31.63, signalling upside risk potential of 7.9%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $15.25 which suggests that it could grow by 7.02%. Given that Arcutis Biotherapeutics, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Arcutis Biotherapeutics, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ARQTArcutis Biotherapeutics, Inc.5 1 0 FOLDAmicus Therapeutics, Inc.3 4 0 -
Is ARQT or FOLD More Risky?
Arcutis Biotherapeutics, Inc. has a beta of 1.693, which suggesting that the stock is 69.345% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.463, suggesting its less volatile than the S&P 500 by 53.675%.
-
Which is a Better Dividend Stock ARQT or FOLD?
Arcutis Biotherapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ARQT or FOLD?
Arcutis Biotherapeutics, Inc. quarterly revenues are $99.2M, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Arcutis Biotherapeutics, Inc.'s net income of $7.4M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Arcutis Biotherapeutics, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics, Inc. is 11.83x versus 7.29x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ARQTArcutis Biotherapeutics, Inc.11.83x -- $99.2M $7.4M FOLDAmicus Therapeutics, Inc.7.29x -- $169.1M $17.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
